Dr. Hill Et al. Meta Analysis Evidences the Promise of Ivermectin: But More Studies Necessary

Dr. Hill Et Al. Meta Analysis Evidences the Promise of Ivermectin: But More Studies Necessary

At the end of 2020, TrialSite reported that Dr. Andrew Hill was conducting a meta-analysis of ivermectin, sponsored by Unitaid, an organization affiliated with the World Health Organization (WHO). In fact, weeks later, Dr. Hill accompanied Dr. Pierre Kory with the Front Line COVID-19 Critical Care Alliance to present to the National Institute of Health (NIH) COVID-19 Treatment Guidelines Panel. An internationally influential investigator, Hill’s ivermectin meta-analysis had ivermectin proponents on an emotional roller coast, first with anticipation that a WHO meeting would use the inputs to declare an emergency use authorization, and then with grief that his findings suggested more research. But Dr. Hill’s paper was published recently in the Oxford Academic Open Forum Infectious Disease Journal. Hill’s results for the anti-parasite medication are impressive. They report a 56% reduction in mortality (Relative Risk 0.44 [95%CI 0.25-0.77]; p=0.004; 35/1064 (3%) deaths on ivermectin; 93/1063 (9%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Seems inconceivable that those statistically significant results don't lea...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee